More: Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
More: Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
More here: argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating...
Go here to read the rest: Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
Originally posted here: Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
Original post: Vor Bio Announces $55.6 Million Private Placement
Go here to read the rest: Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Canid alphaherpesvirus 1 infection alters the gene expression and secretome profile of canine adipose-derived mesenchymal stem cells in vitro Virology Journal
What are stem cells? Stem cells are the foundation cells for every organ, tissue and cell in the body. They are like a blank microchip that can ultimately be programmed to perform particular tasks
Stem cell research has become one of the biggest issues dividing the scientific and religious communities around the world. At the core of the issue is one central question: When does life begin? At this time, to get stem cells that are reliable, scientists either have to use an embryo that has already been conceived or else clone an embryo using a cell from a patient's body and a donated egg.
Abstract Human embryonic stem cells (hESCs), which have the potential to generate virtually any differentiated progeny, are an attractive cell source for transplantation therapy, regenerative medicine, and tissue engineering. To realize this potential, it is essential to be able to control ESC differentiation and to direct the development of these cells along specific pathways. Basic science in the field of embryonic development, stem cell differentiation, and tissue engineering has offered important insights into key pathways and scaffolds that regulate hESC differentiation, which have produced advances in modeling gastrulation in culture and in the efficient induction of endoderm, mesoderm, ectoderm, and many of their downstream derivatives. These findings have lead to identification of several pathways controlling the differentiation of hESCs into mesodermal derivatives such as myoblasts, mesenchymal cells, osteoblasts, chondrocytes, adipocytes, as well as hemangioblastic derivatives. The next challenge will be to demonstrate the functional utility of these cells, both in vitro and in preclinical models of bone and vascular diseases
Recent Comments